Enanta Pharmaceuticals Leadership

Dr. Luly joined Enanta in July 2003. Prior to joining Enanta, Dr. Luly was an Entrepreneur in Residence at Oxford Bioscience Partners. Before joining Oxford in March 2002, Dr. Luly held the positions of Senior Vice President, Research and Development Operations and Senior Vice President, Discovery Strategy and Operations at Millennium Pharmaceuticals following Millennium’s merger with LeukoSite, Inc., where he had served as Senior Vice President, Drug Discovery and Preclinical Development. Prior to joining LeukoSite, he held a number of senior drug discovery positions at Abbott Laboratories from 1983 to 1997. Dr. Luly received a B.S. from the University of Illinois, Urbana/Champaign and a Ph.D. in synthetic organic chemistry from the University of California, Berkeley. Dr. Luly currently serves as a member of the Board of Trustees of the Boston Biomedical Research Institute.

Mr. Mellett joined Enanta in September 2003. From April 2001 through August 2003, he held the position of Senior Vice President and Chief Financial Officer of Essential Therapeutics. Previously, Mr. Mellett was the Chief Financial Officer and Vice President of Administration at GelTex Pharmaceuticals, Inc., a publicly held biotechnology company that was acquired by Genzyme Corporation in December 2000. From 1994 to 1997, Mr. Mellett served as Chief Financial Officer of Marshall Contractors, a construction management firm specializing in the pharmaceutical, biotechnology and semiconductor industries, which was acquired by Fluor Corporation in 1996. From 1977 to 1994, Mr. Mellett was employed with Deloitte & Touche LLP, a public accounting firm, and was promoted to Audit Partner in 1989. Mr. Mellett received a B.S. in Business Administration from Boston College.

Dr. Or joined Enanta in November 1999. Prior to joining Enanta, Dr. Or held key leadership positions at Abbott Laboratories from 1985 to 1999, where he received two Chairman’s Awards for his outstanding research, which led to the discovery and development of numerous immunosuppressant and antibacterial drugs. Prior to Abbott, Dr. Or was a member of the cardiovascular drug discovery team at Schering-Plough. Dr. Or received his Ph.D. in Organic Chemistry from the University of Chicago and completed Postdoctoral Fellowships at Ohio State University and Indiana University.

Nathalie Adda is a graduate of the Paris Medical School (APHP) and a specialist in Infectious Disease (HIV Medicine, Viral Hepatitis). She has more than 20+ years of experience in the pharmaceutical industry with development expertise in all phases of clinical research though NDA and MAA filing and commercialization.She started in the pharmaceutical industry in 1997 and in her current role as Senior Medical Director she is the medical lead HCV and oncology coumpounds Clinical Program at Vertex Pharmaceuticals Inc where she has designed the phase 1 through Phase 3 program. She also led the medical team in its successful marketing applications and registration in several geographies. Prior to her positions in industry she was a Clinical Research Medical Monitor employed by the ANRS (National Agency for Research on AIDS & Hepatitis) where she was in charge of the Research Unit.Overall, in this industry, her main accomplishments focused on designing, developing, planning, and managing global clinical studies, through all phases, that have led to successful registration and commercialization of therapeutics. She has handled projects for unmet medical needs that led to innovative treatments in HIV, HBV and most recently in HCV. She manages both cross-functional working groups, successfully mentors her direct reports. She has authored/co-authored over 130 abstracts, publications, reports & training courses. She has made multiple presentations at national and international scientific meetings and was a key member of the Vertex team at the FDA Antiviral Advisory Committee meeting in April 2011.She has also a past experience in humanitarian and philanthropic activities and has worked in Egypt (Institute of Oncology, Cairo), and Senegal (Sine Saloum, dispensaries).

Dr. Luly joined Enanta in July 2003. Prior to joining Enanta, Dr. Luly was an Entrepreneur in Residence at Oxford Bioscience Partners. Before joining Oxford in March 2002, Dr. Luly held the positions of Senior Vice President, Research and Development Operations and Senior Vice President, Discovery Strategy and Operations at Millennium Pharmaceuticals following Millennium’s merger with LeukoSite, Inc., where he had served as Senior Vice President, Drug Discovery and Preclinical Development. Prior to joining LeukoSite, he held a number of senior drug discovery positions at Abbott Laboratories from 1983 to 1997. Dr. Luly received a B.S. from the University of Illinois, Urbana/Champaign and a Ph.D. in synthetic organic chemistry from the University of California, Berkeley. Dr. Luly currently serves as a member of the Board of Trustees of the Boston Biomedical Research Institute.

Nathalie Adda is a graduate of the Paris Medical School (APHP) and a specialist in Infectious Disease (HIV Medicine, Viral Hepatitis). She has more than 20+ years of experience in the pharmaceutical industry with development expertise in all phases of clinical research though NDA and MAA filing and commercialization.She started in the pharmaceutical industry in 1997 and in her current role as Senior Medical Director she is the medical lead HCV and oncology coumpounds Clinical Program at Vertex Pharmaceuticals Inc where she has designed the phase 1 through Phase 3 program. She also led the medical team in its successful marketing applications and registration in several geographies. Prior to her positions in industry she was a Clinical Research Medical Monitor employed by the ANRS (National Agency for Research on AIDS & Hepatitis) where she was in charge of the Research Unit.Overall, in this industry, her main accomplishments focused on designing, developing, planning, and managing global clinical studies, through all phases, that have led to successful registration and commercialization of therapeutics. She has handled projects for unmet medical needs that led to innovative treatments in HIV, HBV and most recently in HCV. She manages both cross-functional working groups, successfully mentors her direct reports. She has authored/co-authored over 130 abstracts, publications, reports & training courses. She has made multiple presentations at national and international scientific meetings and was a key member of the Vertex team at the FDA Antiviral Advisory Committee meeting in April 2011.She has also a past experience in humanitarian and philanthropic activities and has worked in Egypt (Institute of Oncology, Cairo), and Senegal (Sine Saloum, dispensaries).